Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals

BMC Cancer

Mohammad Sorowar Hossain⁶  Mohd S Iqbal¹²  Mohiuddin Ahmed Khan⁴  Mohammad Golam Rabbani¹¹  Hazera Khatun³  Sirajam Munira¹¹  M Morshed Zaman Miah⁵  Amin Lutful Kabir¹  Naima Islam¹⁰  Tashmim Farhana Dipta⁸  Farzana Rahman⁹  Abdul Mottalib⁸  Salma Afrose⁴  Tasneem Ara⁴  Akhil Ranjan Biswas⁴  Mizanur Rahman⁴  AKM Mustafa Abedin²  Mahbubur Rahman¹⁰  ABM Yunus⁷  Louis W Niessen¹²  Tanvira Afroze Sultana⁸ 

[1] Delta Medical College and Hospital, Dhaka, Bangladesh

[2] Combined Military Hospital, Dhaka, Bangladesh

[3] Square Hospital Ltd, Dhaka, Bangladesh

[4] Dhaka Medical College Hospital, Dhaka, Bangladesh

[5] Rajshahi Medical College Hospital, Rajshahi, Bangladesh

[6] BRAC University, Mohakhali, Dhaka, Bangladesh

[7] Green View Clinic, Dhaka, Bangladesh

[8] BIRDEM General Hospital, Dhaka, Bangladesh

[9] Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

[10] National Institute for Cancer Research and Hospital, Dhaka, Bangladesh

[11] Chittagong Medical College and Hospital, Chittagong, Bangladesh

[12] Centre for Control of Chronic Diseases, icddr’b, Mohakhali, Dhaka, Bangladesh

关键词: Bangladesh;    Hematological malignancy;    MM;    HL;    NHL;    MDS;    ALL;    CML;    AML;   

Others  :  855713
DOI  :  10.1186/1471-2407-14-438

 received in 2013-08-27, accepted in 2014-06-10,  发布年份 2014

【 摘 要 】

Background

The global burden from cancer is rising, especially as low-income countries like Bangladesh observe rapid aging. So far, there are no comprehensive descriptions reporting diagnosed cancer group that include hematological malignancies in Bangladesh.

Methods

This was a multi-center hospital-based retrospective descriptive study of over 5000 confirmed hematological cancer cases in between January 2008 to December 2012. Morphological typing was carried out using the “French American British” classification system.

Results

A total of 5013 patients aged between 2 to 90 years had been diagnosed with malignant hematological disorders. A 69.2% were males (n = 3468) and 30.8% females (n = 1545), with a male to female ratio of 2.2:1. The overall median age at diagnosis was 42 years. Acute myeloid leukemia was most frequent (28.3%) with a median age of 35 years, followed by chronic myeloid leukemia with 18.2% (median age 40 years), non-Hodgkin lymphoma (16.9%; median age 48 years), acute lymphoblastic leukemia (14.1%; median age 27 years), multiple myeloma (10.5%; median age 55 years), myelodysplastic syndromes (4.5%; median age 57 years) and Hodgkin’s lymphoma (3.9%; median age 36 years). The least common was chronic lymphocytic leukemia (3.7%; median age 60 years). Below the age of 20 years, acute lymphoblastic leukemia was predominant (37.3%), followed by acute myeloid leukemia (34%). Chronic lymphocytic leukemia and multiple myeloma had mostly occurred among older patients, aged 50-over.

Conclusions

For the first time, our study presents the pattern and distribution of diagnosed hematological cancers in Bangladesh. It shows differences in population distributions as compared to other settings with possibly a lower presence of non-Hodgkin lymphoma. There might be under-reporting of affected women. Further studies are necessary on the epidemiology, genetics and potential environmental risk factors within this rapidly aging country.

【 授权许可】

   
2014 Hossain et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence, mortality and prevalence worldwide in 2012: GLOBOCAN 2012 v1.0. Lyon, France: International Agency for Research on Cancer; http://globocan.iarc.fr/Default.aspx webcite 2013
• [2]WHO: Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants. 2011.
• [3]Das P, Horton R: Bangladesh: innovating for health. Lancet 2013, 382(9906):1681-1682.
• [4]Hussain SA, Sullivan R: Cancer control in bangladesh. Jpn J Clin Oncol 2013, 43(12):1159-1169.
• [5]Story HL, Love RR, Salim R, Roberto AJ, Krieger JL, Ginsburg OM: Improving outcomes from breast cancer in a low-income country: lessons from Bangladesh. Int J Breast Cancer 2012, 2012:423562.
• [6]Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT: Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood 2012, 119(22):5078-5087.
• [7]Park HJ, Park EH, Jung KW, Kong HJ, Won YJ, Lee JY, Yoon JH, Park BK, Lee H, Eom HS, Park S: Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol 2012, 47(1):28-38.
• [8]Wu SJ, Huang SY, Lin CT, Lin YJ, Chang CJ, Tien HF: The incidence of chronic lymphocytic leukemia in Taiwan, 1986–2005: a distinct increasing trend with birth-cohort effect. Blood 2010, 116(22):4430-4435.
• [9]Fey MF: Salient features of hematological diseases. Ann Oncol 2007, 18(Suppl 1):i54-i64.
• [10]Lichtman MA: Battling the hematological malignancies: the 200 years’ war. Oncologist 2008, 13(2):126-138.
• [11]Rodriguez-Abreu D, Bordoni A, Zucca E: Epidemiology of hematological malignancies. Ann Oncol 2007, 18(Suppl 1):i3-i8.
• [12]Bhutani M, Vora A, Kumar L, Kochupillai V: Lympho-hemopoietic malignancies in India. Med Oncol 2002, 19(3):141-150.
• [13]BRAC: Bangladesh Health System in Transition: Selected Articles (2008). https://www.k4health.org/sites/default/files/bangladesh_health_system_in_transition.pdf webcite
• [14]American Cancer Society: Cancer facts & figures 2012. Atlanta: American cancer society; http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012 webcite
• [15]Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA: Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res 2010, 12(Suppl 4):S8. BioMed Central Full Text
• [16]Parkin D, Ferlay J, Hamdi-Cherif M, Sitas F, Thomas J, Wabinga H, Whelan S: Cancer in Africa: Epidemiology and Prevention. IARC: Lyon; 2003.
• [17]Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O’Neil WM, Saikia TK, Wang J: Chronic myeloid leukemia in Asia. Int J Hematol 2009, 89(1):14-23.
• [18]Mozaheb Z: Epidemiology of Lymphoid Malignancy in Asia, Epidemiology Insights. In Tech Edited by Dr. Maria De Lourdes Ribeiro De Souza Da Cunha. 325-354. doi:10.5772/31746. Available from: http://www.intechopen.com/books/epidemiology-insights/epidemiology-of-lymphoid-malignancy-in-asia webcite. SBN: 978-953-51-0565-7
• [19]Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M: Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005, 106(8):2633-2640.
• [20]Arora RS, Eden TO, Kapoor G: Epidemiology of childhood cancer in India. Indian J Cancer 2009, 46(4):264-273.
• [21]Alexander FE: The search for causes of the leukaemias. Eur J Cancer 1995, 31A(6):863-867.
• [22]Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA: Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1174-1182.
• [23]Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, Rodella S, Tumino R, Crosignani P, Vindigni C, Fontana A, Vineis P, Costantini A: Alcohol consumption and risk of leukemia: a multicenter case–control study. Leuk Res 2007, 31(3):379-386.
• [24]Linet MS, Devesa SS, Morgan GJ: The leukemias. In Cancer epidemiology and prevention. 3rd edition. Edited by Schottenfeld D, Fraumeni JJr. New York: Oxford University Press; 2006:841-871. 2006
• [25]SEER Cancer Statistics Review. 2012. http://seer.cancer.gov/statfacts/html/hodg.html webcite
• [26]Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M: Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica 2012, 98(2):222-229.
• [27]Ibrahim ME, Osman EI: Myeloid Leukemia: A Molecular Focus on Etiology and Risk Within Africa, Myeloid Leukemia - Basic Mechanisms of Leukemogenesis. In Tech Edited by Dr Steffen K. 465-484. DOI: 10.5772/27359. Available from: http://www.intechopen.com/books/myeloid-leukemia-basic-mechanisms-of-leukemogenesis/myeloid-leukemia-a-molecular-focus-on-etiology-and-risk-within-africa webcite. SBN: 978-953-307-789-5
• [28]Hamad HM: Cancer initiatives in Sudan. Ann Oncol 2006, 17(Suppl 8):viii32-viii36.
• [29]Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, Kumar R: Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma 2012, 53(10):1961-1965.
• [30]Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, Uike N, Tsukada J, Kawano F, Shibuya T, Gondo H, Okamura S, Suzumiya J: Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol 2001, 67(3):152-157.
• [31]Clarke CA, Glaser SL, Gomez SL, Wang SS, Keegan TH, Yang J, Chang ET: Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev 2011, 20(6):1064-1077.
• [32]Arora N, Manipadam MT, Nair S: Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013, 54(5):1004-1011.
• [33]Omoti CE, Nwannadi AI, Obieche JC, Olu-Eddo AN: The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. Pan Afr Med J 2012, 11:10.
• [34]Kumar L, Verma R, Radhakrishnan VR: Recent advances in the management of multiple myeloma. Natl Med J India 2010, 23(4):210-218.
• [35]Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O: Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010, 116(25):5501-5506.
• [36]Kar R, Rao S, Saxena R: Myelodysplastic syndromes: classification and prognostic scoring systems and their applicability in Indian scenario-experience from a tertiary care center. Hematology 2009, 14(3):145-149.
• [37]Gattermann N: Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008, 88(1):24-29.